Frontier Diagnostics
Better Diagnostics Saves Lives
Introducing CTC Liquid biopsy breast
cancer clinical trial.
Latest Updates in Cancer Testing
Early detection can improve survival rates by up to 90%. Schedule your test today!
About Us.
Better Diagnostics Saves Lives
Better Diagnostics Saves Lives
Our highest priority is to improve diagnostic and therapeutic approaches to human health. CTC liquid biopsy offeres detection and analysis of important, but rare, cells associated with disease.
Better Diagnostics Saves Lives
- Frontier will provide researchers and oncologists with access to unparalleled precision in molecular characterization.
- Our CELLTRAK® technology provides a simple, minimally invasive liquid biopsy that captures, isolates and enumerates circulating tumor cells (CTCs) for valuable oncologic information to make informed clinical decisions.
The CELLTRAK® CTC Trial
The first and only clinical trial seeking FDA-clearance, a blood test for enumerating circulating tumor cells (CTCs). CTCs are cancer cells that detach from a primary tumor and travel through the bloodstream or lymphatic system to other parts of the body.
Revolutionary Liquid Biopsy Technology
A “liquid biopsy” that can be used at any time during a patient’s course of disease. Performed at our Head Laboratories in Germany. This trial will be processed using the CELLSTRAK® Circulating Tumor Cell System
Our team
Together Defeating Cancer
Better Diagnostics Saves Lives
The CELLTRAK® CTC trial is a simple, actionable blood test that helps oncologists assess the prognosis of patients with metastatic breast, prostate* , or colorectal cancer.
Sport&Science
As an adjunct to standard methods of monitoring, the CELLTRAK® CTC Test provides:
An early assessment of patient prognosis Detection of changes in prognosis at any time The most accurate assessment of prognosis in cases where CTC and imaging are discordant in patients with metastatic breast cancer, and in cases where CTC and PSA are discordant in patients with metastatic prostate cancer
References:
Cristofanilli M, Hayes DF, Budd GT, et al. J Clin Oncol. 2005;23(7):1420-1430.
de Bono JS, Scher HI, Montgomery RB, et al. Clin Cancer Res. 2008;14:6302-6309.
Cohen SJ, Punt CJA, Iannotti N, et al. J Clin Oncol. 2008;26(19):3213-3221.
Frontier Diagnostics supports a healthy active lifestyle via international sports sponsorship events: sport can cut risk of illness by over 50%
Information for Oncologists
CTCs are a strong, independent predictor of overall and progression-free survival in metastatic breast, prostate* and colorectal cancer
Use the CELLTRAK ® CTC Test to inform clinical decisions in patients with metastatic breast, prostate* and colorectal cancerat any time during the course of disease
Start testing patients
Clinical studies validate the predictive accuracy of the CELLTRAK system, if you wish to learn more or recommend patients for the trials please contact:
info@frontierdiagnostics.net
Your Journey to Early Detection, Step by Step.
Understanding the testing process can ease your concerns and help you prepare. Here’s what to expect when you choose [Your Company Name] for your cancer testing needs:
Consultation
Meet with our specialists to discuss your health history and concerns
Personalized Testing Plan
Based on your needs, we’ll recommend the most suitable tests to detect any signs of cancer.
Testing
Our cutting-edge technology ensures that your tests are performed with precision and care.
Results & Next Steps
Our team will explain your results in detail and guide you through any follow-up steps or treatments if necessary.